Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, November 7, 2026

Back to the front page

From X

@aleabitoreddit

Serenity on X

The two things I'm excited about are Gen G vs. T1... and new NASA's $10 Billion contract to begin settling on the moon. NASA selected: - $SPCX (SpaceX) - Blue Origin - $FLY (Firefly) - $LUNR (Lunar) - $LMT (Lockheed Martin Space) - $NOC (Northrop Grumman Space) - $VOYG (Voyager) - iSpace US to compete for future lunar delivery missions - $1.3B in launch and orbital transportation orders awarded to Arrow Science, Blue Origin, and Impulse Space. - $94 million for Blue Origin to deliver NASA's nuclear powered PROMISE rover - Existing CLPS 1 contract ceiling raised from $2.6B to $4.2B. - NASA also announced awards to Honeybee Robotics, a Blue Origin company, $RDW for a lunar power and communications tower
@leevalueroach

Lee Roach on X

Any rational person should lever themselves up until infinity on 0% convertible debt when rates are pushing 6%. You would be irrational to not do that. Especially if you are any good at capital allocation. How do you think $GME got $5bn of cash on the balance sheet and 10% of eBay. Oh and they made over $1bn in mark to market returns on eBay so far. And 6% on the remaining $5bn is $300 million of interest income per year. All for a zero percent convert that is still out of the money. One of the best capital allocation moves I’ve ever seen on Wall Street.
@SouthernValue95

SouthernValue on X

When I do AI supply and demand modeling, everything ex-SPCX generally fits together and makes sense and is reasonably well funded. No individual large build looks too excessive because, for the most part, large projects are pre sold before they are built, or at least before they are completed… Anthropic can fund its ambitions for the next few years pretty easily with ARR and cash on hand. Even OpenAI is sitting on a mountain of cash and can fund the majority of compute with ARR. The hyperscale clouds are allocating between internal, lab, and enterprise use cases. This changed w/ $SPCX who is trying to build ~40% of 2026 capacity next year but without a secured buyer. Just a massive bet that industry capacity plans will undershoot realized demand by a wide margin. This is the most obvious way this becomes a glut. And everything else will mostly be contracted, with spcx holding most of the bag. They also have BY FAR the most financial upside if conditions remain tight, because of their chosen path to live and die by the spot market. But I find it puzzling that markets have really not challenged them more, particularly as broadly the risk of a cyclical peak comes into focus. When parties as risk seeking as OpenAI @sama have called them speculative (one of only 2-3 potential buyers of SPCX capacity…). Also SPCX two existing customers are abundantly clear that they view their contracts as short-term / bridge capacity and intend to churn off as new cheaper capacity comes online at ~1/5 of the price.

Investor Letters

All letters

Post Q3 EVC Update

EVC's Q3 update cites $30 million for a single station, a broadcast-business sale and stronger positioning for 2027.

EVC $832M
Nat Stewart - Stock Picking Newsletter 23 clicks

Entravision Q3 Update

Entravision’s Q3 ad-tech revenue reached $177.2 million, up 133% year over year, while total revenue rose 88% to $226.3 million and diluted…

EVC $832M
The Value Road 4 clicks

Axon 3Q26 Business Update

Axon cut full-year guidance after delayed federal Dedrone contracts slowed 3Q revenue growth to 28%, while software and services grew 43%.

AXON $31B
Speedwell Memos 3 clicks
GPC · long

Genuine Parts CO

Genuine Parts trades at roughly 9x EBITDA as cyclical weakness and elevated NAPA investment temporarily depress earnings.

GPC $17B
Value Investors Club 2 clicks

A Mexican Blue Chip Bargain

Grupo Herdez, a MXN 15.2 billion Mexican food company, pairs dominant grocery brands with McCormick, Barilla and Hormel joint ventures.

GUZOF $951M
Exploring with Alluvial Capital

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $1.9B
John Hempton's Newsletter 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 279

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.